Table 2. Relationship between CLDN4 expression and clinicopathological parameters in differentiated and undifferentiated types of gastric cancer.
| Differentiated cases1 | Undifferentiated cases2 | |||||
|---|---|---|---|---|---|---|
| n | Expression index3 | P4 | n | Expression index3 | P4 | |
| Parameters5 | ||||||
| pT | ||||||
| 1–2 | 85 | 195 ± 9 | 45 | 157 ± 12 | ||
| 3–4 | 27 | 190 ± 12 | NS | 25 | 107 ± 17 | < 0.05 |
| pN | ||||||
| 0 | 96 | 194 ± 8 | 63 | 135 ± 10 | ||
| 1–3 | 16 | 198 ± 21 | NS | 7 | 174 ± 37 | NS |
| pStage | ||||||
| I | 77 | 196 ± 10 | 43 | 149 ± 12 | ||
| II–IV | 35 | 190 ± 13 | NS | 27 | 123 ± 17 | NS |
1Differentiated gastric cancer contains papillary adenocarcinoma, well-differentiated tubular and moderately differentiated tubular adenocarcinoma.
2Undifferentiated gastric cancer contains poorly differentiated adenocarcinoma, signet-ring cell carcinoma and mucinous adenocarcinoma.
3Claudin-4 (CLDN4) expression index was calculated as the staining strength score multiplied by the staining area.
4P value was calculated by ordinary ANOVA test. NS, not significant.
5pT1–2, tumor confined within the submucosa or tumor invades the muscularis propria; pT3–4, tumor invades the subserosa or tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent structures; pN0, no regional lymph node metastasis; pN1–3, metastasis in 1 or more regional lymph nodes; pStage I, pT1 and pN0 or pN1, or pT2 and pN0, pStage II–IV, all cases other than pStage I [34].